Coactinon’s last act
Executive Summary
Triangle Pharmaceuticals terminates development of Coactinon (emivirine) after analysis shows non-nucleoside reverse transcriptase inhibitor did not perform as well as comparator drug abacavir (GlaxoSmithKline's Ziagen) across full study population in Phase III trial...